As the national voice for Canadian heart failure specialists, the CHFS is frequently approached with requests from various organizations for endorsement.
The CHFS supports projects that align with our mission to improve the care of patients through research, advocacy, education and development of best practices in the field of heart failure disorders.
We are proud to offer our support to the following important initiatives and programs.
New Resource: Practical Approach to SGLT2 Inhibitors for the Treatment of Cardiovascular Disease
The Canadian Heart Failure Society is pleased to provide cardiologists with a practical algorithm for the use of SGLT2 inhibitors in the prevention and treatment of cardiomyopathies and cardiovascular diseases. This two-page resource was created by a CHFS committee composed of Dr. Jonathan Howlett (Chair), Dr. Kim Connelly, Dr. Eileen O’Meara and Dr. Shelley Zieroth.
This document was made possible through a sponsorship from AstraZeneca and the Boehringer-Ingelheim – Lilly Alliance.
ATTR Amyloidosis On-Demand Learning Activities
The CHFS is pleased to provide Canadian healthcare professionals with two 50-60 minute accredited on-demand learning activities on the topic of ATTR amyloidosis. These symposia were originally offered as part of the 2020 Heart Failure Update Congress.
Click on the links below to watch the webinar or download the presentation:
- Beyond Awareness: How to Diagnose and Treat Hereditary ATTR Amyloidosis in your Practice
- Treating Wild-Type ATTR Cardiac Amyloidosis Today
These on-demand learning activities expire in April 17, 2021
Reflective Learning: New Treatment Options in HFrEF
Reflective Learning: New Treatment Options in HFrEF is a Section 3 MOC learning activity accredited by the Canadian Cardiovascular Society (CCS) and endorsed by the Canadian Heart Failure Society (CHFS). The program is intended to serve as a valuable resource to help you optimize treatment decisions related to the management of patients with HFrEF within your practice.
The program expires on March 31, 2021.
CHFS/Pfizer Cardiac Amyloidosis Knowledge Translation Initiative
Amyloid (ATTR) cardiomyopathy now has new treatment options. A comprehensive education program, developed through the CHFS, will ensure that the information can reach a broad audience across the cardiovascular community in Canada. Heightened awareness of the condition will ensure more timely diagnosis and optimal management of patients with this complex disease.
In Progress 2020
CHFS/Servier Collaboration on Heart Failure Knowledge Translation
The Canadian Heart Failure Society (CHFS) is pleased to provide details on an educational program focused on providing high quality continuing medical education and professional development on best practices for the treatment of heart failure. The program is targeted at the entire spectrum of healthcare providers and will take place in communities across Canada. The CHFS has developed a suite of educational resources including traditional CME, webinars and a self-reflective learning program, which leverages previous initiatives. A primary goal of creating such a program is to tailor local educational programs to meet the diverse needs of learners.
The focus of these educational programs and knowledge translation activities is to increase awareness of heart failure, including the disease burden and outcomes, provide tools and resources to support patients and practitioners and to highlight evidence based strategies for treatment optimization.
ESC 2019 Late-breaking Highlights in Heart Failure
"ESC Congress 2019, which was held this year with the World Congress of Cardiology, certainly will be remembered as an exceptional vintage,” said Professor Marco Roffi, M.D., chair of the ESC Congress Programme Committee. The focus of this year’s late breaking trials was undoubtedly on heart failure, and PARAGON-HF, DAPA-HF, and PROVE-HF will no doubt influence practice. As part of its mandate to disseminate new knowledge, the Canadian Heart Failure Society is pleased to provide this summary and analysis of key heart failure trials reported at ESC 2019.
Read the CHFS' perspective on heart failure trials released at ESC 2019:
University of Waterloo SPOR Initiative
In addition, to the extensive range of research on aging and health within the University of Waterloo (UW), the Centre initiative will build on UW capacity to serve as a hub in a network-of-networks with a common emphasis on aging. UW will facilitate linkages among researchers through these networks to engage in research with direct relevance to strategy for patient-oriented research (SPOR) priorities in Ontario.
This initiative will establish the University of Waterloo Centre on Aging (UWCA) as a SPOR Unit focused on patient oriented research on aging and health.
Heart failure is the initial focus of this project and CHFS is pleased to support this real world pragmatic trial which also engages both patients and caregivers.
This project has an overarching role of optimizing patient care and the treatment of patients suffering from acute HF and chronic HF with the view of enhancing the quality of care for such patients.Novartis will collaborate with approximately 10 institutions across Canada from both academic and community centers in order to obtain a comprehensive national portrait of acute heart failure care in Canada.
The CAN-HF initiative has an overarching goal of optimizing patient care and the treatment of patients suffering from acute heart failure and chronic heart failure. As such, we are proud to offer our support to this important initiative.